While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...

Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

Sunnova Energy International's poison pill comes after the company said its status as a going concern was at risk, announced job cuts and named a new CEO. Houston-based solar energy company ...

European fintech Pliant has reportedly acquired the Austrian Insurtech hi.health. The acquisition enables Pliant to apply its payment expertise to the insurance sector while “gaining industry ...

Perion Network's board adopted a limited-duration shareholder-rights plan, more commonly known as a poison pill. Under the plan, the advertising-technology company will issue one right for each of ...

Boaz Weinstein, Founder and Chief Investment Officer of Saba, commented: “By readopting a poison pill that was already deemed unlawful, ASA, Chair Mary Joan Hoene and Director William Donovan ...